白细胞介素-23抑制剂治疗银屑病的研究进展

Research progress of interleukin-23 inhibitors in treating psoriasis

银屑病是一种常见的慢性炎症性皮肤病,严重威胁人类的身心健康,已受到国内外学者的广泛关注,但银屑病的确切发病机制和病因尚不清楚。近年来,以抑制相应的免疫反应靶点的多种生物制剂在对中至重度银屑病的治疗上取得了显著的疗效。大量的试验和临床研究证实白细胞介素-23(interleukin-23,IL-23)在银屑病的发病机制中发挥了重要的作用。目前,针对IL-23靶点开发治疗银屑病的新药已经取得了很大进展。本文就IL-23抑制剂对银屑病治疗的研究进展进行综述。

Psoriasis is a common chronic inflammatory dermatosis,which seriously threatens the physical and mental health of human beings and is widely concerned by scholars at home and abroad.However,the exact pathogenesis and etiology of psoriasis is not clear.In recent years,various biological agents that inhibit the corresponding target of immune response have achieved remarkable curative effect in the treatment of moderate to severe psoriasis.A large number of experimental and clinical studies have confirmed that interleukin-23（IL-23）plays an important role in the pathogenesis of psoriasis.At present,great progress has been made in the development of new drugs for the treatment of psoriasis against the IL-23 target.This article reviews the progress of IL-23 inhibitors in the treatment of psoriasis.